VolitionRx’s (VNRX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of VolitionRx (NYSE:VNRX) in a research note published on Wednesday,Benzinga reports. The firm currently has a $5.00 price target on the stock.

A number of other equities analysts also recently issued reports on the stock. StockNews.com started coverage on shares of VolitionRx in a report on Wednesday. They issued a “sell” rating for the company. Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Stock Performance

Shares of VolitionRx stock opened at $0.57 on Wednesday. The company has a market cap of $52.45 million, a P/E ratio of -1.57 and a beta of 1.09. VolitionRx has a one year low of $0.43 and a one year high of $1.04. The firm has a fifty day moving average of $0.61 and a two-hundred day moving average of $0.65.

Institutional Investors Weigh In On VolitionRx

A number of large investors have recently added to or reduced their stakes in the business. Two Sigma Securities LLC acquired a new stake in shares of VolitionRx during the 4th quarter worth about $29,000. Millennium Management LLC acquired a new stake in shares of VolitionRx during the 4th quarter worth about $36,000. Northern Trust Corp boosted its stake in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. boosted its stake in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares during the last quarter. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.